Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered Entry - Earnings Revision

Live News

As of April 23, 2026, 11:54 UTC, Johnson & Johnson (NYSE: JNJ) was featured as a top bullish pick on Jim Cramer’s *Mad Money* program, with Cramer announcing that his Charitable Trust had initiated a position in the stock during the ongoing sector-wide pullback. Cramer noted that pharma is currently deeply out of favor with market participants, who have rotated heavily into high-growth AI and cyclical industrial names so far this year, creating a rare opportunity to buy high-quality healthcare a Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryReal-time monitoring of multiple asset classes can help traders manage risk more effectively. By understanding how commodities, currencies, and equities interact, investors can create hedging strategies or adjust their positions quickly.Many investors now incorporate global news and macroeconomic indicators into their market analysis. Events affecting energy, metals, or agriculture can influence equities indirectly, making comprehensive awareness critical.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryThe integration of AI-driven insights has started to complement human decision-making. While automated models can process large volumes of data, traders still rely on judgment to evaluate context and nuance.

Key Highlights

1. **Valuation Profile**: JNJ currently trades at 13.2x forward 12-month price-to-earnings (P/E), a 22% discount to its 5-year historical average of 16.9x, and an 18% discount to the large-cap pharma peer group average of 16.1x. The stock also offers a 3.1% annual dividend yield, with 59 consecutive years of dividend increases, earning it Dividend King status, one of only 48 U.S. public companies to hold the designation. 2. **Icotyde Catalyst**: Consensus sell-side estimates project Icotyde will Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryCross-asset analysis can guide hedging strategies. Understanding inter-market relationships mitigates risk exposure.Observing correlations between markets can reveal hidden opportunities. For example, energy price shifts may precede changes in industrial equities, providing actionable insight.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryMonitoring global indices can help identify shifts in overall sentiment. These changes often influence individual stocks.

Expert Insights

Cramer’s bullish call on JNJ aligns with core portfolio construction principles he cited from his tenure at Goldman Sachs, noting that “assets do not appreciate in unison, and defensive exposure is critical to mitigating drawdowns in growth-heavy portfolios.” With a 5-year beta of 0.62, JNJ is 38% less volatile than the broader S&P 500, making it an ideal hedge for investors holding concentrated positions in high-beta AI and tech stocks that have led 2026 market gains. That said, investors should weigh material downside risks before initiating a position. JNJ’s top-selling immunology drug Stelara loses U.S. exclusivity in 2027, with consensus estimates projecting the loss of $2.1 billion in annual revenue by 2028 before Icotyde and other pipeline assets can offset the decline. Additionally, proposed U.S. drug pricing reforms could compress margins for JNJ’s top 10 selling products by an estimated 7% to 9% if passed in their current form. Consensus analyst ratings remain largely bullish on JNJ, with 18 of 24 covering analysts assigning a Buy or Strong Buy rating, and a weighted average 12-month price target of $187, implying 21% upside from JNJ’s April 23 closing price of $154.50. For investors seeking higher short-term upside, as noted in recent market analysis, select undervalued AI plays positioned to benefit from onshoring trends and Trump-era tariff policies may offer higher risk-adjusted returns, though these assets carry far higher volatility and drawdown risk than JNJ. Overall, JNJ represents a high-quality defensive play for long-term investors with moderate risk tolerance, and the current sector selloff offers a rare entry point to one of the U.S.’s most consistent operational performers. For growth-focused investors, a 5% to 10% portfolio allocation to JNJ can provide meaningful downside protection without sacrificing long-term total return potential, balancing exposure to high-growth segments that dominate current market momentum. (Word count: 1172) Disclosure: No holdings in JNJ or mentioned AI securities as of publication. Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryMonitoring the spread between related markets can reveal potential arbitrage opportunities. For instance, discrepancies between futures contracts and underlying indices often signal temporary mispricing, which can be leveraged with proper risk management and execution discipline.Some traders prioritize speed during volatile periods. Quick access to data allows them to take advantage of short-lived opportunities.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntrySome traders prioritize speed during volatile periods. Quick access to data allows them to take advantage of short-lived opportunities.